Central regions | Finance, business | Technology & innovation

Skolkovo resident develops diabetic foot treatment

10 Jun '19
A young Russian company called NextGene, a resident of the Skolkovo Technopark just outside Moscow, is working on its proprietary new technology that is expected to help diabetic foot syndrome patients.

The diabetic foot syndrome is one of the most widespread diabetes complications, responsible for 75% of nontraumatic lower extremities amputations globally.

This past spring Russias Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, announced support for the young developer. Of the $492,000 grant funding, an estimated $246,000 came from Skolkovo and HSCI was expected to match the amount. NextGene wanted to use the money to complete phase 2 of clinical trials for its new therapy.

Experts were reported to have found no analog of the new substance in the market.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Tags: Human Stem Cells Institute (9) / grant (36) / Skolkovo Foundation (33) / diabetic foot (0) / NextGene (0) /

Latest News: Central regions
19 Aug '19 | Finance, business | Technology & innovation
19 Aug '19 | Technology & innovation
16 Aug '19 | Finance, business | Telecoms, media
16 Aug '19 | Technology & innovation
15 Aug '19 | Finance, business | Technology & innovation

Feature stories

25 Jul '19
Russian scientists have come up with a new method of...
26 May '19
This article has been written by Carl Burch, an MBA,...
4 Apr '19
Russian scientists have come up with what they say is...
Search (News archive - 21430)
Marchmont News

Latest News

19 Aug '19
Stickeroid AI, a machine learning developer of...
16 Aug '19
MTS, one of Russias main mobile operators, earlier...
15 Aug '19
International investors have given the Russian Direct...

Most read stories from last week

19 Aug '19
Stickeroid AI, a machine learning developer of...